solute carrier family 28 member 2Genealiases: CNT2 · HCNT2 · HsT17153 · SPNT1
Q-omics provides the consensus-scored SLC28A2 profile across patient tissues and cancer cell-line models. SLC28A2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SLC28A2 is differentially expressed in 10, with the highest sampling consensus in KIRP. Additionally, SLC28A2 protein abundance shows 28,249 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, KIRP, and LSCC as cancer lineages where SLC28A2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC28A2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC28A2 survival associations across molecular data types. SLC28A2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC28A2 RNA expression–survival associations across cancer types. High SLC28A2 expression shows unfavorable associations in KIRC, CHOL, UVM and ACC, but favorable associations in OV and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KIRC as the clearest survival context for SLC28A2 RNA expression.
This table summarizes SLC28A2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SLC28A2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC28A2 shows lower tumor expression in KIRP, KIRC, COAD, KICH and READ and higher tumor expression in LUAD. The KIRP box plot shows higher SLC28A2 RNA expression in normal versus tumor tissue (log2 FC = −1.736, t-test p < 0.001).
This table shows molecular features associated with SLC28A2 in patient tissues and cancer cell lines. In patient samples, SLC28A2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC28A2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and SOFT_TISSUE.
